Step 1: What ESBLs do.
Extended-spectrum beta-lactamases are enzymes that hydrolyse penicillins, oxyimino-cephalosporins (3rd-generation cephalosporins such as ceftriaxone, ceftazidime, cefotaxime) and aztreonam. They are inhibited by clavulanic acid in vitro but this does not translate into reliable clinical efficacy.
Step 2: Statement on carbapenems (TRUE).
Carbapenems (meropenem, imipenem, ertapenem) are the drugs of choice for serious ESBL infections — they are stable to ESBL hydrolysis.
Step 3: Statement on plasmid transmission (TRUE).
ESBL genes (e.g. CTX-M, TEM, SHV) are carried on plasmids, allowing horizontal spread and co-resistance to other antibiotic classes.
Step 4: Why piptaz and 3rd-gen cephalosporins are wrong.
By definition ESBLs hydrolyse 3rd-generation cephalosporins, so these must NOT be used even if the lab reports apparent susceptibility. Piperacillin-tazobactam is not a reliable first-line agent for serious ESBL infection (inoculum effect, variable outcomes), so it is not the correct answer.
Key fact: ESBL = plasmid-mediated, hydrolyses 3rd-gen cephalosporins; treat serious infection with a carbapenem.